Drucken
Marktanalyse - Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H1 2012
Global Markets Direct
4 / 2012
119 Seiten
| Typ: | Marktanalyse |
| Sprache: | Englisch |
| Regionen: | Europa, Asien / Pazifik, Mittlerer Osten / Afrika, Nordamerika / USA, Australien, Mittel- / Südamerika |
| Verfügbarkeit: | verfügbar |
Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:
Acute Renal Failure (ARF) (Acute Kidney Injury) — Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Acute Renal Failure (ARF) (Acute Kidney Injury).
- A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Acute Renal Failure (ARF) (Acute Kidney Injury).
- A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) 11
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Products under Development by Companies 21
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Products under Investigation by Universities/Institutes 22
Companies Involved in Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics Development 23
FibroGen, Inc. 23
Novartis AG 24
Bayer AG 25
Cleveland BioLabs, Inc. 26
Torrent Pharmaceuticals Limited 27
Am-Pharma B.V. 28
AlloCure Inc. 29
Angion Biomedica Corp. 30
Thrasos, Inc. 31
CorMedix, Inc. 32
Exponential Biotherapies, Inc. 33
Action Pharma A/S 34
Kringle Pharma, Inc. 35
Nephrx Corporation 36
Acute Renal Failure (ARF) (Acute Kidney Injury) — Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
FG-3019 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Protectan CBLB502 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Bovine Alkaline Phosphatase (iv) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
EA-230 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
EA-230 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BB3 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
QPI 1002 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Eculizumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ChronSeal - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Lenalidomide + Dexamethasone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
N-Acetylcysteine + Deferoxamine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Bortezomib + Dexamethasone + Doxorubicin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 62
Acetylcysteine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Erythropoietin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Imatinib Mesylate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AP214 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Atorvastatin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Sodium Bicarbonate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Velcade + Dexamethasone - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Bendavia - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Fenoldopam - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Ketanserin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CRMD-001 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
NX001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Bortezomib + Dexamethasone - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cyclophosphamide + Bortezomib + Dexamethasone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Curcumin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Nautiol - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Pentoxifylline - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Selenium - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Fenoldopam - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Furosemide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
BCT197 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Mesenchymal Stromal Cells - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
HIF - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
THR-184 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
AC607 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Intravenous Recombinant Alkaline Phosphatase - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
BR-5489 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Recombinant Human HGF - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Drug Profile Updates 100
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Discontinued Products 109
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Dormant Products 110
Acute Renal Failure (ARF) (Acute Kidney Injury) — Product Development Milestones 111
Featured News & Press Releases 111
Jan 05, 2012: AlloCure's Investigational Treatment For Acute Kidney Injury Receives Fast Track Designation From FDA 111
Nov 14, 2011: AlloCure Presents Safety And Preliminary Efficacy Of AC607 For Treatment Of Acute Kidney Injury At American Society Of Nephrology 111
Oct 03, 2011: Journal of Immunology Publishes Study Of Cleveland BioLabs's CBLB502 In Acute Renal Ischemic Failure 112
Sep 26, 2011: Action Pharma’s Phase IIb Clinical Trial With AP214 To Prevent Kidney Injury Associated With Major Cardiac Surgery Demonstrates Positive Top-Line Results 113
Sep 13, 2011: Thrasos Initiates Phase I Clinical Trial Of THR-184 In Acute Kidney Injury 114
Aug 08, 2011: Final Patient Completes Last Visit In Action Pharma’s Phase IIb Clinical Trial Of Ap214 115
Jun 21, 2011: CorMedix Announces SPA Agreement With FDA For Phase III Trial Of CRMD001 Study In Prevention Of CI-AKI 115
May 09, 2011: Action Pharma Completes Dosing In Phase IIb Clinical Trial With AP214 To Prevent Acute Kidney Injury Undergoing Cardiac Surgery 116
Jul 06, 2010: Angion Biomedica Receives Fast Track And Orphan Drug Designations From FDA For BB3 116
Mar 10, 2010: AM-Pharma Presents Positive Results of Its Phase II Clinical Trial With Alkaline Phosphatase in Acute Kidney Injury At The ISICEM Conference In Brussels 117
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 119
Disclaimer 119
List of Tables
Number of Products Under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2012 11
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) — Comparative Analysis, H1 2012 12
Number of Products under Development by Companies, H1 2012 14
Number of Products under Investigation by Universities/Institutes, H1 2012 16
Comparative Analysis by Late Stage Development, H1 2012 17
Comparative Analysis by Mid Clinical Stage Development, H1 2012 18
Comparative Analysis by Early Clinical Stage Development, H1 2012 19
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 20
Products under Development by Companies, H1 2012 21
Products under Investigation by Universities/Institutes, H1 2012 22
FibroGen, Inc., H1 2012 23
Novartis AG, H1 2012 24
Bayer AG, H1 2012 25
Cleveland BioLabs, Inc., H1 2012 26
Torrent Pharmaceuticals Limited, H1 2012 27
Am-Pharma B.V., H1 2012 28
AlloCure Inc., H1 2012 29
Angion Biomedica Corp., H1 2012 30
Thrasos, Inc., H1 2012 31
CorMedix, Inc., H1 2012 32
Exponential Biotherapies, Inc., H1 2012 33
Action Pharma A/S, H1 2012 34
Kringle Pharma, Inc., H1 2012 35
Nephrx Corporation, H1 2012 36
Assessment by Monotherapy Products, H1 2012 37
Assessment by Combination Products, H1 2012 38
Assessment by Stage and Route of Administration, H1 2012 40
Assessment by Stage and Molecule Type, H1 2012 43
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Drug Profile Updates 100
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Discontinued Products 109
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Dormant Products 110
List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2012 11
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) — Comparative Analysis, H1 2012 12
Products under Development by Companies, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 15
Late Stage Products, H1 2012 17
Mid Clinical Stage Products, H1 2012 18
Early Clinical Stage Products, H1 2012 19
Pre-Clinical Stage Products, H1 2012 20
Assessment by Monotherapy Products, H1 2012 37
Assessment by Combination Products, H1 2012 38
Assessment by Route of Administration, H1 2012 39
Assessment by Stage and Route of Administration, H1 2012 40
Assessment by Molecule Type, H1 2012 41
Assessment by Stage and Molecule Type, H1 2012 42
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) 11
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Products under Development by Companies 21
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Products under Investigation by Universities/Institutes 22
Companies Involved in Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics Development 23
FibroGen, Inc. 23
Novartis AG 24
Bayer AG 25
Cleveland BioLabs, Inc. 26
Torrent Pharmaceuticals Limited 27
Am-Pharma B.V. 28
AlloCure Inc. 29
Angion Biomedica Corp. 30
Thrasos, Inc. 31
CorMedix, Inc. 32
Exponential Biotherapies, Inc. 33
Action Pharma A/S 34
Kringle Pharma, Inc. 35
Nephrx Corporation 36
Acute Renal Failure (ARF) (Acute Kidney Injury) — Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 44
FG-3019 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Protectan CBLB502 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Bovine Alkaline Phosphatase (iv) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
EA-230 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
EA-230 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BB3 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
QPI 1002 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Eculizumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ChronSeal - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Lenalidomide + Dexamethasone - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
N-Acetylcysteine + Deferoxamine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Bortezomib + Dexamethasone + Doxorubicin - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 62
Acetylcysteine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Erythropoietin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Imatinib Mesylate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AP214 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Atorvastatin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Sodium Bicarbonate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Velcade + Dexamethasone - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Bendavia - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Fenoldopam - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Ketanserin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
CRMD-001 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
NX001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Bortezomib + Dexamethasone - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Cyclophosphamide + Bortezomib + Dexamethasone - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Curcumin - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Nautiol - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Pentoxifylline - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Selenium - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Fenoldopam - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Furosemide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
BCT197 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Mesenchymal Stromal Cells - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
HIF - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
THR-184 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
AC607 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Intravenous Recombinant Alkaline Phosphatase - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
BR-5489 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Recombinant Human HGF - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Drug Profile Updates 100
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Discontinued Products 109
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Dormant Products 110
Acute Renal Failure (ARF) (Acute Kidney Injury) — Product Development Milestones 111
Featured News & Press Releases 111
Jan 05, 2012: AlloCure's Investigational Treatment For Acute Kidney Injury Receives Fast Track Designation From FDA 111
Nov 14, 2011: AlloCure Presents Safety And Preliminary Efficacy Of AC607 For Treatment Of Acute Kidney Injury At American Society Of Nephrology 111
Oct 03, 2011: Journal of Immunology Publishes Study Of Cleveland BioLabs's CBLB502 In Acute Renal Ischemic Failure 112
Sep 26, 2011: Action Pharma’s Phase IIb Clinical Trial With AP214 To Prevent Kidney Injury Associated With Major Cardiac Surgery Demonstrates Positive Top-Line Results 113
Sep 13, 2011: Thrasos Initiates Phase I Clinical Trial Of THR-184 In Acute Kidney Injury 114
Aug 08, 2011: Final Patient Completes Last Visit In Action Pharma’s Phase IIb Clinical Trial Of Ap214 115
Jun 21, 2011: CorMedix Announces SPA Agreement With FDA For Phase III Trial Of CRMD001 Study In Prevention Of CI-AKI 115
May 09, 2011: Action Pharma Completes Dosing In Phase IIb Clinical Trial With AP214 To Prevent Acute Kidney Injury Undergoing Cardiac Surgery 116
Jul 06, 2010: Angion Biomedica Receives Fast Track And Orphan Drug Designations From FDA For BB3 116
Mar 10, 2010: AM-Pharma Presents Positive Results of Its Phase II Clinical Trial With Alkaline Phosphatase in Acute Kidney Injury At The ISICEM Conference In Brussels 117
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 119
Disclaimer 119
List of Tables
Number of Products Under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2012 11
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) — Comparative Analysis, H1 2012 12
Number of Products under Development by Companies, H1 2012 14
Number of Products under Investigation by Universities/Institutes, H1 2012 16
Comparative Analysis by Late Stage Development, H1 2012 17
Comparative Analysis by Mid Clinical Stage Development, H1 2012 18
Comparative Analysis by Early Clinical Stage Development, H1 2012 19
Comparative Analysis by Pre-Clinical Stage Development, H1 2012 20
Products under Development by Companies, H1 2012 21
Products under Investigation by Universities/Institutes, H1 2012 22
FibroGen, Inc., H1 2012 23
Novartis AG, H1 2012 24
Bayer AG, H1 2012 25
Cleveland BioLabs, Inc., H1 2012 26
Torrent Pharmaceuticals Limited, H1 2012 27
Am-Pharma B.V., H1 2012 28
AlloCure Inc., H1 2012 29
Angion Biomedica Corp., H1 2012 30
Thrasos, Inc., H1 2012 31
CorMedix, Inc., H1 2012 32
Exponential Biotherapies, Inc., H1 2012 33
Action Pharma A/S, H1 2012 34
Kringle Pharma, Inc., H1 2012 35
Nephrx Corporation, H1 2012 36
Assessment by Monotherapy Products, H1 2012 37
Assessment by Combination Products, H1 2012 38
Assessment by Stage and Route of Administration, H1 2012 40
Assessment by Stage and Molecule Type, H1 2012 43
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Drug Profile Updates 100
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Discontinued Products 109
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics — Dormant Products 110
List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2012 11
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) — Comparative Analysis, H1 2012 12
Products under Development by Companies, H1 2012 13
Products under Investigation by Universities/Institutes, H1 2012 15
Late Stage Products, H1 2012 17
Mid Clinical Stage Products, H1 2012 18
Early Clinical Stage Products, H1 2012 19
Pre-Clinical Stage Products, H1 2012 20
Assessment by Monotherapy Products, H1 2012 37
Assessment by Combination Products, H1 2012 38
Assessment by Route of Administration, H1 2012 39
Assessment by Stage and Route of Administration, H1 2012 40
Assessment by Molecule Type, H1 2012 41
Assessment by Stage and Molecule Type, H1 2012 42
- Growth Hormone Deficiency – Pipeline Review, H1 2013
- Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
- Growth Disorders – Pipeline Review, H1 2013
- Kidney Fibrosis – Pipeline Review, H1 2013
- Urinary Incontinence – Pipeline Review, H1 2013
- Global Endocrinology Drugs Market 2012-2016
- Inguinal Hernia Global Clinical Trials Review, H1, 2013
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
- Microalbuminuria – Pipeline Review, H2 2012
- Nocturia – Pipeline Review, H2 2012
- Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
- Hypoparathyroidism – Pipeline Review, H2 2012
- Proteinuria – Pipeline Review, H2 2012
- Thyroid Gland Disorders – Pipeline Review, H2 2012
- Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
- Hypothyroidism Global Clinical Trials Review, H2, 2012
- Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
- Other Genito Urinary Disorders – Pipeline Review, H2 2012
- Urinary Retention Global Clinical Trials Review, H2, 2012
- Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012
*Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.
Hinweise: **The report can be shared by users within one office (one geographical location)
***Across Geographical locations (by the purchasing company only)
Für Sie protokollierte Studien / Marktanalysen:
zuletzt angesehene Studien: